Weekly Digest – January 2026 Weekly Digest – January 2026 22 January 2026: ENHERTU approved in China as the first and only HER2 directed ADC for the second-Line treatment of patients with HER2 positive metastatic gastric cancer ENHERTU (trastuzumab deruxtecan) has been approved in China for the second-line treatment of adults with […]
Weekly Digest – January 2026 Weekly Digest – January 2026 21 January 2026: Daiichi Sankyo Korea and AstraZeneca Korea receive approval for Enhertu for patients with HER2 low- and ultra-low-expression metastatic breast cancer treated with endocrine therapy Daiichi Sankyo Korea and AstraZeneca Korea announced that Enhertu (trastuzumab deruxtecan) has received approval from Korea’s Ministry of Food […]
Weekly Digest – January 2026 Weekly Digest – January 2026 20 January 2026: Lilly’s sofetabart mipitecan receives U.S. FDA’s Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer Eli Lilly announced that the U.S. FDA has […]
Weekly Digest – January 2026 Weekly Digest – January 2026 21 January 2026: Sichuan Baili Tianheng Pharmaceutical’s BL-B01D1 marketing application (NDA) has been formally accepted by China’s National Medical Products Administration (NMPA) Sichuan Baili Tianheng Pharmaceutical announced that China’s National […]
Weekly Digest – January 2026 Weekly Digest – January 2026 21 January 2026: Avacta announces U.S. Food and Drug Administration clearance of the Investigational New Drug (IND) application for the second pre|CISION medicine, FAP-Exatecan (AVA6103) Avacta Therapeutics announced that the U.S. […]
Weekly Digest – January 2026 Weekly Digest – January 2026 19 January 2026: Ellipses in-licenses first-in-class B7H3 Antibody Drug Conjugate from China Ellipses Pharma announced that it has entered into a collaboration and licensing agreement with Innolake Biopharm to in-license […]
